LPL Financial LLC Acquires 3,264 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• LPL Financial LLC increased its holdings in Jazz Pharmaceuticals by 14.5%, acquiring an additional 3,264 shares, bringing its total ownership to 25,769 shares valued at approximately $3.2 million.
• Multiple institutional investors, including Dimensional Fund Advisors LP and Ameriprise Financial Inc., have also raised their stakes in Jazz Pharmaceuticals, reflecting strong institutional interest with 89.14% of the stock owned by institutional investors.
• Jazz Pharmaceuticals reported a disappointing earnings per share of ($8.25) for the last quarter, falling short of analysts' estimates and indicating challenges despite a slight revenue increase of 2.1% year over year.

LPL Financial LLC raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 14.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,769 shares of the specialty pharmaceutical company's stock after buying an additional 3,264 shares during the quarter. LPL Financial LLC's holdings in Jazz Pharmaceuticals were worth $3,199,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Townsquare Capital LLC boosted its holdings in shares of Jazz Pharmaceuticals by 79.5% in the 4th quarter. Townsquare Capital LLC now owns 3,540 shares of the specialty pharmaceutical company's stock worth $436,000 after purchasing an additional 1,568 shares in the last quarter. Barclays PLC boosted its holdings in shares of Jazz Pharmaceuticals by 70.2% in the 4th quarter. Barclays PLC now owns 66,728 shares of the specialty pharmaceutical company's stock worth $8,216,000 after purchasing an additional 27,518 shares in the last quarter. Mariner LLC boosted its holdings in shares of Jazz Pharmaceuticals by 33.9% in the 4th quarter. Mariner LLC now owns 26,803 shares of the specialty pharmaceutical company's stock worth $3,301,000 after purchasing an additional 6,782 shares in the last quarter. Evergreen Capital Management LLC boosted its holdings in shares of Jazz Pharmaceuticals by 7.1% in the 4th quarter. Evergreen Capital Management LLC now owns 4,097 shares of the specialty pharmaceutical company's stock worth $505,000 after purchasing an additional 273 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $7,313,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating for the company in a report on Wednesday, August 6th. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $181.43.

Jazz Pharmaceuticals Trading Up 1.2%

Shares of NASDAQ JAZZ traded up $1.46 during midday trading on Thursday, reaching $120.53. The company had a trading volume of 747,352 shares, compared to its average volume of 822,084. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm's fifty day moving average price is $112.44 and its 200-day moving average price is $117.14. The stock has a market cap of $7.31 billion, a PE ratio of -17.91, a price-to-earnings-growth ratio of 7.50 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.30% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.